PICKERING GRANT sold $111K of PCVX (indirect holdings)
PICKERING GRANT (CHIEF EXECUTIVE OFFICER) sold 2,000 indirectly-held shares of Vaxcyte, Inc. (PCVX) at an average of $55.65 ($55.52–$55.96, $0.11M total) across 4 trades on 2026-07-27 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
This provides a concrete datapoint on insider selling activity (2,000 shares, ~$111.3K) but does not disclose any new company performance, guidance, regulatory, or deal information.
Market read
Traders may briefly factor in insider selling optics, but the 10b5-1 designation and lack of fundamental updates suggest limited trading edge.
What to watch
The sale is indirect and under a pre-arranged plan, which reduces interpretability; without context on total insider holdings and prior sale cadence, signal quality is limited.
Background
The article is an SEC Form 4 insider transaction disclosure for Vaxcyte, Inc. (PCVX) by CEO Pickering Grant, indicating an open-market sale under a Rule 10b5-1 plan.
Ticker impact
SEC Form 4 shows CEO Pickering Grant sold 2,000 shares of Vaxcyte (PCVX) for about $111.3K on 2026-07-27 under a 10b5-1 plan.
Low near-term impact; any reaction is likely muted and short-lived unless follow-on filings show unusual selling patterns.
The filing is a Form 4 insider transaction, explicitly marked as pre-arranged 10b5-1, and provides only sale details without new company fundamentals.
Market effects
Minimal; single-company insider liquidity event in biotech/healthcare with no sector-wide datapoint.
None indicated.
None indicated.
Counterpoint
Even with 10b5-1, repeated or larger-than-usual insider selling can coincide with management de-risking ahead of catalysts, so traders may watch for clustering of similar sales.
Key entities
- issuerVaxcyte, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderPickering Grant
CEO and director who executed the sale under a 10b5-1 plan.
